Read the latest positive news, breakthroughs, and inspiring stories about lecanemab, curated daily by BrightWire.
New research from Duke Health reveals that 80% of patients with early-stage Alzheimer's stayed on a breakthrough medication for over a year, with most side effects resolving on their own. The findings bring hope to families navigating treatment options for this devastating disease.
A newly approved Alzheimer's treatment in Malaysia can slow disease progression by more than eight years, giving patients precious extra time with their independence and loved ones. Unlike previous treatments that only managed symptoms, lecanemab actually changes how the disease progresses.
Over 90% of Alzheimer's patients in Japan continue treatment with Lecanemab without serious side effects, new research confirms. The breakthrough drug slows disease progression by targeting brain plaque buildup.
After two decades of setbacks, scientists have achieved a major breakthrough with Lecanemab, the first fully approved treatment that actually slows Alzheimer's progression. Over 200 more potential treatments are now racing through clinical trials, bringing real hope to millions of families.
